Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid

The development of effective delivery systems for antitumor drugs with increased specificity and controlled release is one of the challenges for biomedical chemistry. This paper presents studies of non-covalent interactions of human serum albumin, which may be a promising carrier for drug delivery,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry Biomedical chemistry, 2024-09, Vol.18 (3), p.231-242
Hauptverfasser: Bauer, I. A., Dmitrienko, E. V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 242
container_issue 3
container_start_page 231
container_title Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry
container_volume 18
creator Bauer, I. A.
Dmitrienko, E. V.
description The development of effective delivery systems for antitumor drugs with increased specificity and controlled release is one of the challenges for biomedical chemistry. This paper presents studies of non-covalent interactions of human serum albumin, which may be a promising carrier for drug delivery, with antitumor antibiotic doxorubicin and folic acid, which have the potential of a guide ligand. Intermolecular interactions of doxorubicin and folic acid with human serum albumin were studied by spectroscopic methods at various pH levels and temperatures. The binding strength of doxorubicin and folic acid responded differently to pH changes. The affinity of the drug to protein increased with the transition from acidic to alkaline conditions, while pH 7.4 was optimal for binding for folic acid. In the case of the triple system, it was found that there was no significant effect of albumin complexation with folic acid on non-covalent interaction with doxorubicin. As expected, binding to these active compounds altered the conformation of the protein. At the same time, this change was minimal in physiological pH for folic acid and in alkaline for doxorubicin. Additionally, the therapeutic properties of doxorubicin, non-covalently bound to human serum albumin, were shown to be preserved in vitro.
doi_str_mv 10.1134/S1990750823600413
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3124606194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3124606194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c198t-5f83af9f834a6c19c0e746c3745439f72bd0b067d62e1d61fe0d7c5cc76bcae73</originalsourceid><addsrcrecordid>eNp1UMFOAyEUJEYTa_UDvJF4XoWFheXYVGubNHqoXt2wLFSaXaiwW_XvpanRg_Hy3stkZl5mALjE6BpjQm9WWAjEC1TmhCFEMTkCoz2U8QKz458blafgLMYNQgwTQUfgZeF2OvZ2LXvr1vDBu2zqd7LVrocL1-sgVW-9i9AbOB866eBKh6GDk7YeOuvgu-1f4a3_8GGorUqAdA2c-dYqOFG2OQcnRrZRX3zvMXie3T1N59ny8X4xnSwzhUXZZ4UpiTQiTSpZghTSnDJFOC0oEYbndYNqxHjDco0bho1GDVeFUpzVSmpOxuDq4LsN_m1IgaqNH4JLLyuCc8pSXEETCx9YKvgYgzbVNthOhs8Ko2pfY_WnxqTJD5qYuG6tw6_z_6IvIEF0WQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3124606194</pqid></control><display><type>article</type><title>Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid</title><source>Springer Nature - Complete Springer Journals</source><creator>Bauer, I. A. ; Dmitrienko, E. V.</creator><creatorcontrib>Bauer, I. A. ; Dmitrienko, E. V.</creatorcontrib><description>The development of effective delivery systems for antitumor drugs with increased specificity and controlled release is one of the challenges for biomedical chemistry. This paper presents studies of non-covalent interactions of human serum albumin, which may be a promising carrier for drug delivery, with antitumor antibiotic doxorubicin and folic acid, which have the potential of a guide ligand. Intermolecular interactions of doxorubicin and folic acid with human serum albumin were studied by spectroscopic methods at various pH levels and temperatures. The binding strength of doxorubicin and folic acid responded differently to pH changes. The affinity of the drug to protein increased with the transition from acidic to alkaline conditions, while pH 7.4 was optimal for binding for folic acid. In the case of the triple system, it was found that there was no significant effect of albumin complexation with folic acid on non-covalent interaction with doxorubicin. As expected, binding to these active compounds altered the conformation of the protein. At the same time, this change was minimal in physiological pH for folic acid and in alkaline for doxorubicin. Additionally, the therapeutic properties of doxorubicin, non-covalently bound to human serum albumin, were shown to be preserved in vitro.</description><identifier>ISSN: 1990-7508</identifier><identifier>EISSN: 1990-7516</identifier><identifier>DOI: 10.1134/S1990750823600413</identifier><language>eng</language><publisher>Moscow: Pleiades Publishing</publisher><subject>Acids ; Antitumor activity ; Bioorganic Chemistry ; Chemistry ; Chemistry and Materials Science ; Controlled release ; Doxorubicin ; Drug delivery ; Drug development ; Drug interaction ; Folic acid ; Human serum albumin ; Medicinal Chemistry ; pH effects ; Protein structure ; Proteins ; Vitamin B</subject><ispartof>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry, 2024-09, Vol.18 (3), p.231-242</ispartof><rights>Pleiades Publishing, Ltd. 2024. ISSN 1990-7508, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 2024, Vol. 18, No. 3, pp. 231–242. © Pleiades Publishing, Ltd., 2024.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c198t-5f83af9f834a6c19c0e746c3745439f72bd0b067d62e1d61fe0d7c5cc76bcae73</cites><orcidid>0000-0002-2295-6455 ; 0000-0003-4555-5774</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1134/S1990750823600413$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1134/S1990750823600413$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids></links><search><creatorcontrib>Bauer, I. A.</creatorcontrib><creatorcontrib>Dmitrienko, E. V.</creatorcontrib><title>Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid</title><title>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry</title><addtitle>Biochem. Moscow Suppl. Ser. B</addtitle><description>The development of effective delivery systems for antitumor drugs with increased specificity and controlled release is one of the challenges for biomedical chemistry. This paper presents studies of non-covalent interactions of human serum albumin, which may be a promising carrier for drug delivery, with antitumor antibiotic doxorubicin and folic acid, which have the potential of a guide ligand. Intermolecular interactions of doxorubicin and folic acid with human serum albumin were studied by spectroscopic methods at various pH levels and temperatures. The binding strength of doxorubicin and folic acid responded differently to pH changes. The affinity of the drug to protein increased with the transition from acidic to alkaline conditions, while pH 7.4 was optimal for binding for folic acid. In the case of the triple system, it was found that there was no significant effect of albumin complexation with folic acid on non-covalent interaction with doxorubicin. As expected, binding to these active compounds altered the conformation of the protein. At the same time, this change was minimal in physiological pH for folic acid and in alkaline for doxorubicin. Additionally, the therapeutic properties of doxorubicin, non-covalently bound to human serum albumin, were shown to be preserved in vitro.</description><subject>Acids</subject><subject>Antitumor activity</subject><subject>Bioorganic Chemistry</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Controlled release</subject><subject>Doxorubicin</subject><subject>Drug delivery</subject><subject>Drug development</subject><subject>Drug interaction</subject><subject>Folic acid</subject><subject>Human serum albumin</subject><subject>Medicinal Chemistry</subject><subject>pH effects</subject><subject>Protein structure</subject><subject>Proteins</subject><subject>Vitamin B</subject><issn>1990-7508</issn><issn>1990-7516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1UMFOAyEUJEYTa_UDvJF4XoWFheXYVGubNHqoXt2wLFSaXaiwW_XvpanRg_Hy3stkZl5mALjE6BpjQm9WWAjEC1TmhCFEMTkCoz2U8QKz458blafgLMYNQgwTQUfgZeF2OvZ2LXvr1vDBu2zqd7LVrocL1-sgVW-9i9AbOB866eBKh6GDk7YeOuvgu-1f4a3_8GGorUqAdA2c-dYqOFG2OQcnRrZRX3zvMXie3T1N59ny8X4xnSwzhUXZZ4UpiTQiTSpZghTSnDJFOC0oEYbndYNqxHjDco0bho1GDVeFUpzVSmpOxuDq4LsN_m1IgaqNH4JLLyuCc8pSXEETCx9YKvgYgzbVNthOhs8Ko2pfY_WnxqTJD5qYuG6tw6_z_6IvIEF0WQ</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Bauer, I. A.</creator><creator>Dmitrienko, E. V.</creator><general>Pleiades Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-2295-6455</orcidid><orcidid>https://orcid.org/0000-0003-4555-5774</orcidid></search><sort><creationdate>20240901</creationdate><title>Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid</title><author>Bauer, I. A. ; Dmitrienko, E. V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c198t-5f83af9f834a6c19c0e746c3745439f72bd0b067d62e1d61fe0d7c5cc76bcae73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Antitumor activity</topic><topic>Bioorganic Chemistry</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Controlled release</topic><topic>Doxorubicin</topic><topic>Drug delivery</topic><topic>Drug development</topic><topic>Drug interaction</topic><topic>Folic acid</topic><topic>Human serum albumin</topic><topic>Medicinal Chemistry</topic><topic>pH effects</topic><topic>Protein structure</topic><topic>Proteins</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bauer, I. A.</creatorcontrib><creatorcontrib>Dmitrienko, E. V.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bauer, I. A.</au><au>Dmitrienko, E. V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid</atitle><jtitle>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry</jtitle><stitle>Biochem. Moscow Suppl. Ser. B</stitle><date>2024-09-01</date><risdate>2024</risdate><volume>18</volume><issue>3</issue><spage>231</spage><epage>242</epage><pages>231-242</pages><issn>1990-7508</issn><eissn>1990-7516</eissn><abstract>The development of effective delivery systems for antitumor drugs with increased specificity and controlled release is one of the challenges for biomedical chemistry. This paper presents studies of non-covalent interactions of human serum albumin, which may be a promising carrier for drug delivery, with antitumor antibiotic doxorubicin and folic acid, which have the potential of a guide ligand. Intermolecular interactions of doxorubicin and folic acid with human serum albumin were studied by spectroscopic methods at various pH levels and temperatures. The binding strength of doxorubicin and folic acid responded differently to pH changes. The affinity of the drug to protein increased with the transition from acidic to alkaline conditions, while pH 7.4 was optimal for binding for folic acid. In the case of the triple system, it was found that there was no significant effect of albumin complexation with folic acid on non-covalent interaction with doxorubicin. As expected, binding to these active compounds altered the conformation of the protein. At the same time, this change was minimal in physiological pH for folic acid and in alkaline for doxorubicin. Additionally, the therapeutic properties of doxorubicin, non-covalently bound to human serum albumin, were shown to be preserved in vitro.</abstract><cop>Moscow</cop><pub>Pleiades Publishing</pub><doi>10.1134/S1990750823600413</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2295-6455</orcidid><orcidid>https://orcid.org/0000-0003-4555-5774</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1990-7508
ispartof Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry, 2024-09, Vol.18 (3), p.231-242
issn 1990-7508
1990-7516
language eng
recordid cdi_proquest_journals_3124606194
source Springer Nature - Complete Springer Journals
subjects Acids
Antitumor activity
Bioorganic Chemistry
Chemistry
Chemistry and Materials Science
Controlled release
Doxorubicin
Drug delivery
Drug development
Drug interaction
Folic acid
Human serum albumin
Medicinal Chemistry
pH effects
Protein structure
Proteins
Vitamin B
title Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A56%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigating%20Non-Covalent%20Interactions%20of%20Human%20Serum%20Albumin%20with%20Doxorubicin%20and%20Folic%20Acid&rft.jtitle=Biochemistry%20(Moscow).%20Supplement.%20Series%20B,%20Biomedical%20chemistry&rft.au=Bauer,%20I.%20A.&rft.date=2024-09-01&rft.volume=18&rft.issue=3&rft.spage=231&rft.epage=242&rft.pages=231-242&rft.issn=1990-7508&rft.eissn=1990-7516&rft_id=info:doi/10.1134/S1990750823600413&rft_dat=%3Cproquest_cross%3E3124606194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3124606194&rft_id=info:pmid/&rfr_iscdi=true